The combination of nivolumab with an interleukin-15 agonist was well tolerated with no dose-limiting toxicities in patients with metastatic non–small-cell lung cancer.
Original Article: New Option in NSCLC With IL-15 Agonist Plus Immune Checkpoint Inhibition